| P50 | author | Kanta Subbarao | Q37377392 |
| | Kylie M. Quinn | Q55473611 |
| | Annette Fox | Q56840041 |
| P2093 | author name string | Annette Fox | |
| | Kylie M Quinn | |
| P2860 | cites work | Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses | Q24615003 |
| | Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals | Q24648051 |
| | Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses | Q24649949 |
| | Immunoregulatory functions of immune complexes in vaccine and therapy | Q26738396 |
| | A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus | Q27316330 |
| | A structural basis for immunodominant human T cell receptor recognition | Q27641421 |
| | Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities | Q27681214 |
| | Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection | Q27701887 |
| | A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen | Q27701889 |
| | Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis | Q28073431 |
| | Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets | Q28384099 |
| | Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses | Q28387782 |
| | Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge | Q28392109 |
| | AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland | Q28730881 |
| | Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial | Q30203099 |
| | Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection | Q30209769 |
| | Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults | Q30227196 |
| | Avian influenza h6 viruses productively infect and cause illness in mice and ferrets | Q30228780 |
| | Cellular immune correlates of protection against symptomatic pandemic influenza. | Q30353819 |
| | International flight-related transmission of pandemic influenza A(H1N1)pdm09: an historical cohort study of the first identified cases in the United Kingdom. | Q30357321 |
| | A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. | Q30359896 |
| | Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. | Q30366666 |
| | Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. | Q30369136 |
| | A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. | Q30370303 |
| | Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. | Q30371866 |
| | Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study | Q30373419 |
| | Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study. | Q30374107 |
| | ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. | Q30375901 |
| | Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype | Q30376605 |
| | A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. | Q30377443 |
| | Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant | Q30381280 |
| | Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. | Q30382343 |
| | Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). | Q30382351 |
| | Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains | Q30382895 |
| | Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity | Q30382921 |
| | Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets | Q30383905 |
| | Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. | Q30384878 |
| | Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus. | Q30388110 |
| | Live attenuated influenza virus vaccines by computer-aided rational design | Q30390286 |
| | M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice | Q30392561 |
| | Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination | Q30395263 |
| | Development of clade-specific and broadly reactive live attenuated influenza virus vaccines against rapidly evolving H5 subtype viruses. | Q30401838 |
| | Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial | Q30402307 |
| | Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans | Q30412301 |
| | Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines | Q30420898 |
| | Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity | Q30421682 |
| | CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection | Q37547668 |
| | A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses | Q37585518 |
| | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses | Q37690439 |
| | T cell responses to viral infections - opportunities for Peptide vaccination | Q37718978 |
| | T-cell immunity to influenza A viruses | Q38191991 |
| | Development and applications of single-cycle infectious influenza A virus (sciIAV). | Q38556537 |
| | Developments in Viral Vector-Based Vaccines | Q38582090 |
| | Evaluation of the biological properties and cross-reactive antibody response to H10 influenza viruses in ferrets | Q38682074 |
| | Generation of influenza A viruses as live but replication-incompetent virus vaccines | Q38726947 |
| | Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain | Q38773338 |
| | Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion | Q38786915 |
| | Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection | Q38795680 |
| | Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies | Q38803189 |
| | Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? | Q38804059 |
| | Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses | Q39196481 |
| | Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines | Q39320852 |
| | Influenza at Christ's Hospital: March, 1974. | Q39362382 |
| | A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus | Q39397313 |
| | The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen | Q39521975 |
| | Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults | Q39744811 |
| | Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge | Q36231145 |
| | Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes | Q36353327 |
| | Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets | Q36569494 |
| | Functional Significance of Sialidase During Influenza Virus Multiplication: an Electron Microscope Study | Q36575180 |
| | Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination | Q36752092 |
| | Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine. | Q36754401 |
| | Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection | Q36781677 |
| | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | Q36911722 |
| | Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets | Q37033178 |
| | Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children | Q37083489 |
| | Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model | Q37123064 |
| | Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection | Q37123679 |
| | Antiviral Activity of Antiserum Specific for an Influenza Virus Neuraminidase | Q37129134 |
| | Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice | Q37131450 |
| | Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus | Q37207762 |
| | Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection | Q37496801 |
| | Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge | Q30421687 |
| | Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine | Q30425439 |
| | Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase | Q30425783 |
| | Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis | Q30427647 |
| | Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells | Q33782214 |
| | Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells | Q33792922 |
| | Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity | Q33813612 |
| | Innate immunity to influenza virus infection | Q33923354 |
| | Influenza virus vaccine based on the conserved hemagglutinin stalk domain | Q34030587 |
| | TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination | Q34216832 |
| | Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus | Q34261441 |
| | Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein | Q34261503 |
| | A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys | Q34295941 |
| | T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine | Q34338986 |
| | Preferential localization of effector memory cells in nonlymphoid tissue | Q34514330 |
| | Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion | Q34615273 |
| | Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis | Q34783486 |
| | An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults | Q35017702 |
| | Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine | Q35110968 |
| | Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children | Q35167127 |
| | Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. | Q35531941 |
| | Ab and T cell epitopes of influenza A virus, knowledge and opportunities | Q35575957 |
| | Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology | Q35746101 |
| | Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues | Q35936035 |
| | Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived | Q35974418 |
| | Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine | Q35987793 |
| | Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans | Q36014866 |
| | Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model | Q36099034 |
| | Selection of antigenically advanced variants of seasonal influenza viruses | Q36116332 |
| | Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy | Q36125875 |
| | Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms | Q36129141 |
| | Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets | Q36139178 |
| | Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity | Q36227268 |
| | Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells | Q36230446 |
| | Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition | Q40047277 |
| | Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization | Q40056879 |
| | Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. | Q40116170 |
| | M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza | Q40138342 |
| | PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+ T cell responses | Q40198556 |
| | Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes | Q40592083 |
| | Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus | Q40674956 |
| | Evaluation of a Neuraminidase-Specific Influenza A Virus Vaccine in Children: Antibody Responses and Effects on Two Successive Outbreaks of Natural Infection | Q41179647 |
| | Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection | Q41347626 |
| | Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. | Q41546303 |
| | Abundance and specificity of influenza reactive circulating memory follicular helper and non-follicular helper CD4 T cells in healthy adults | Q41654157 |
| | Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. | Q41933365 |
| | A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine | Q41997487 |
| | An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera | Q42186897 |
| | Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population | Q42195595 |
| | A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. | Q42212558 |
| | Universal anti-neuraminidase antibody inhibiting all influenza A subtypes | Q42264969 |
| | MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination | Q43258765 |
| | Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses | Q44031168 |
| | Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. | Q44109738 |
| | Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response | Q44237462 |
| | An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine | Q44248046 |
| | Association of serum anti-neuraminidase antibody with resistance to influenza in man. | Q44693807 |
| | A recombinant viruslike particle influenza A (H7N9) vaccine | Q44831356 |
| | Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin | Q45132598 |
| | Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus | Q45385806 |
| | Human memory CTL response specific for influenza A virus is broad and multispecific | Q45742987 |
| | Virus-specific CD8+ T cells in primary and secondary influenza pneumonia | Q45755057 |
| | Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice | Q45765023 |
| | Correlated Studies of a Recombinant Influenza-Virus Vaccine. III. Protection against Experimental Influenza in Man | Q45813455 |
| | Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees | Q45830670 |
| | Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses | Q46737829 |
| | Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines | Q47130066 |
| | Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes | Q50146914 |
| | Cutting edge: local recall responses by memory T cells newly recruited to peripheral nonlymphoid tissues. | Q51961185 |
| | The vast majority of CLA+ T cells are resident in normal skin. | Q51984006 |
| | Dynamics of blood-borne CD8 memory T cell migration in vivo. | Q52000583 |
| | Declining T-cell immunity to influenza, 1977-82 | Q52214753 |
| | Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. | Q52602393 |
| | Comparison of Heterosubtypic Protection in Ferrets and Pigs Induced by a Single-Cycle Influenza Vaccine. | Q54226450 |
| | Induction of Partial Immunity to Influenza by a Neuraminidase-specific Vaccine | Q54467457 |
| | Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. | Q54981943 |
| | Immunity to influenza in ferrets. 13. Protection against influenza infection by serum antibody to homologous haemagglutinin or neuraminidase antigens | Q68810477 |
| | In vivo veritas: the surprising roles of Fc receptors in immunity | Q82908543 |
| | Computationally optimized antigens to overcome influenza viral diversity | Q83547970 |
| | Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial | Q84104357 |
| | DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials | Q85047234 |
| | Effect of neuraminidase antibody on Hong Kong influenza | Q93737304 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 1297-1308 | |
| P577 | publication date | 2018-08-07 | |
| | 2018-09-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine | |
| P478 | volume | 78 | |